Pasar al contenido principal

NUEVAS INTERVENCIONES TERAPEUTICAS MULTIDOMINIO PARA RETRASAR LA FRAGILIDAD Y LA DISCAPACIDAD. IDENTIFICACION DE MECANISMOS MOLECULARES CON RELEVANCIA TRASLACIONAL

PID2019-110906RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models

  • Costa-Machado, Luis Filipe
  • Fabregat-Safont, David
  • Pozo Mendoza, Óscar J., 1975-
  • Fernandez-Marcos, Pablo J.
Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis., Work in the laboratory of P.J.F.-M. was funded by the IMDEA Food Institute, the Ramón Areces Foundation (CIVP18A3891), the AECC (SIRTBIO, LABAE18008FERN), the MICINN (SAF2017-85766-R and PRPPID2020-114077RB-I00) co-funded by the European Regional Development Fund, and a Ramon y Cajal Fellowship (MICINN, RYC-2017-22335). J.L.L.-A. was funded by the Spanish Ministry of Science and Innovation (MICINN) (PTA2017‐14689‐I). Work in FreshAge laboratory was funded by: Instituto de Salud Carlos III CB16/10/00435 (CIBERFES), (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science; FGCSIC/PSLINTERREG/FEDER; PROMETEO/2019/097 de “Consellería de Sanitat de la Generalitat Valenciana” and EU Funded H2020- DIABFRAIL-LATAM (Ref: 825546). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana). Support from Ramón Areces Fundation and Soria Melguizo Foundation is also acknowledged. E.G.-D. was a recipient of a predoctoral grant financed by the Spanish Ministry (FPU18/05350). Work in the laboratory of IdP was funded by the MICINN (RTI2018-100872-J-I00) and PlaGenT excellence research program of the Valencian regional government (CIDENGENT/2019/044). Work in the laboratory of M.-I.G. was funded by PROMETEU/2018/135 from “Consellería, de Sanitat de la Generalitat Valenciana” and part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020). F.M. is grateful to the Austrian Science Fund FWF (SFB-LIPOTOX F3007 & F3012, W1226, P29203, P29262, P27893, and P31727); the Austrian Federal Ministry of Education, Science and Research and the University of Graz for grants Unkonventionelle Forschung-InterFast and ysleep (BMWFW-80.109/0001-WF/V/3b/2015) and the field of excellence program BioHealth. We acknowledge support from NAWI Graz, the BioTechMed-Graz agship project EPIAge. T.E. acknowledges support from Austrian Science Fund FWF (P 33957 and TAI 602 1000). Work in the laboratory of R.H.H. was financially supported by a VIDI grant from ZonMw (no. 91715305). J.S.D. was supported by Ohio University. D.F.-S. acknowledges Ministerio de Universidades in Spain for his Margarita Salas postdoctoral grant (Ref. MGS/2021/15). The CGC group is funded by NIH Office of Research Infrastructure Programs (P40 OD010440).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Adult Neural Stem Cell Migration Is Impaired in a Mouse Model of Alzheimer&apos, s Disease

  • Esteve, Daniel
  • Molina-Navarro, María Micaela
  • Martínez-Varea, Noelia
  • Blanco-Gandia, Mari Carmen
  • Rodríguez-Arias, Marta
  • García-Verdugo, Jose Manuel
  • Viña, José
  • Lloret, Ana
  • Giraldo, Esther|||0000-0001-5488-3011
[EN] Neurogenesis in the adult brain takes place in two neurogenic niches: the ventricular-subventricular zone (V-SVZ) and the subgranular zone. After differentiation, neural precursor cells (neuroblasts) have to move to an adequate position, a process known as neuronal migration. Some studies show that in Alzheimer's disease, the adult neurogenesis is impaired. Our main aim was to investigate some proteins involved both in the physiopathology of Alzheimer's disease and in the neuronal migration process using the APP/PS1 Alzheimer's mouse model. Progenitor migrating cells are accumulated in the V-SVZ of the APP/PS1 mice. Furthermore, we find an increase of Cdh1 levels and a decrease of Cdk5/p35 and cyclin B1, indicating that these cells have an alteration of the cell cycle, which triggers a senescence state. We find less cells in the rostral migratory stream and less mature neurons in the olfactory bulbs from APP/PS1 mice, leading to an impaired odour discriminatory ability compared with WT mice. Alzheimer's disease mice present a deficit in cell migration from V-SVZ due to a senescent phenotype. Therefore, these results can contribute to a new approach of Alzheimer's based on senolytic compounds or pro-neurogenic factors., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the following grants: Instituto de Salud Carlos III CB16/10/00435 (CIBER-FES), (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science, PROMETEO/2019/097 from `Conselleria, de Sanitat de la Generalitat Valenciana' and EU Funded H2020-DIABFRAIL-LATAM (Ref: 825546), European Joint Programming Initiative `A Healthy Diet for a Healthy Life' (JPI HDHL) and of the ERA-NET Cofound ERA-HDHL (GA No 696295 of the EU Horizon 2020 Research and Innovation Programme). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020). Special Research Actions from University of Valencia (REF: UV-INV-AE-1546096).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer s Disease

  • Monllor, Paloma
  • Badia, Mari-Carmen
  • García de la Asunción, José
  • Alonso, Maria-Dolores
  • Lloret, Ana
  • Viña, Jose
  • Giraldo, Esther|||0000-0001-5488-3011
[EN] Background: Alzheimer's disease (AD) is the most common form of dementia and biomarkers are essential to help in the diagnosis of this disease. Image techniques and cerebrospinal fluid (CSF) biomarkers are limited in their use because they are expensive or invasive. Thus, the search for blood-borne biomarkers is becoming central to the medical community. Objective: The main objective of this study is the evaluation of three serum proteins as potential biomarkers in AD patients. Methods: We recruited 27 healthy controls, 19 mild cognitive impairment patients, and 17 AD patients. Using the recent A/T/N classification we split our population into two groups (AD and control). We used ELISA kits to determine Aß42, tau, and p-tau in CSF and clusterin, PKR, and RAGE in serum. Results: The levels of serum clusterin, PKR, and RAGE were statistically different in the AD group compared to controls. These proteins showed a statistically significant correlation with CSF Aß42. So, they were selected to generate an AD detection model showing an AUC-ROC of 0.971 (CI 95%, 0.931-0.998). Conclusion: The developed model based on serum biomarkers and other co-variates could reflect the AD core pathology. So far, not one single blood-biomarker has been described, with effectiveness offering high sensitivity and specificity. We propose that the complexity of AD pathology could be reflected in a set of biomarkers also including clinical features of the patients., This work was supported by the following grants: Instituto de Salud Carlos III CB16/10/00435 (CIBE RFES), (PID2019-110906RB-I00/AEI/10.13039/50 1100011033) from the Spanish Ministry of Innovation and Science, PROMETEO/2019/097 de "Conselleria, de Sanitat de la Generalitat Valenciana" and EU Funded H2020-DIABFRAIL-LATAM(Ref: 825546), European Joint Programming Initiative "A Healthy Diet for a Healthy Life" (JPI HDHL) and of the ERA-NET Cofund ERA-HDHL (GA N. 696295 of the EU Horizon 2020 Research and Innovation Programme). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020). We also thank Mrs Marilyn Noyes for her kind help in reviewing the manuscript. The authors thank Francisco Santonja for the statistical analysis support.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial

  • José, Viña
  • Escudero, Joaquín
  • Baquero, Miquel
  • Cebrián, Mónica
  • Carbonell Asíns, Juan Antonio
  • Muñoz, José Enrique
  • Satorres, Encarnación
  • Meléndez, Juan Carlos
  • Ferrer Rebolleda, José
  • Cózar Santiago, Mª Del Puig
  • Santabárbara Gómez, Jose Manuel
  • Jové Font, Mariona
  • Pamplona Gras, Reinald
  • Tarazona Santabalbina, Francisco José
  • Borrás, Consuelo
Background: Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet efective substances are recommended. There is a need to develop new drugs to delay Alzheimer’s dementia. We have taken a nutritional supplement approach with genistein, a chemically defned polyphenol that acts by multimodal specifc mechanisms. Our group previously showed that genistein supplementation is efective to treat the double transgenic (APP/PS1) AD animal model. Methods: In this double-blind, placebo-controlled, bicentric clinical trial, we evaluated the efect of daily oral supplementation with 120 mg of genistein for 12 months on 24 prodromal Alzheimer’s disease patients. The amyloidbeta deposition was analyzed using 18F-futemetamol uptake. We used a battery of validated neurocognitive tests: Mini-Mental State Exam (MMSE), Memory Alteration Test (M@T), Clock Drawing Test, Complutense Verbal Learning Test (TAVEC), Barcelona Test-Revised (TBR), and Rey Complex Figure Test. Results: We report that genistein treatment results in a signifcant improvement in two of the tests used (dichotomized direct TAVEC, p=0.031; dichotomized delayed Centil REY copy p=0.002 and a tendency to improve in all the rest of them. The amyloid-beta deposition analysis showed that genistein-treated patients did not increase their uptake in the anterior cingulate gyrus after treatment (p=0.878), while placebo-treated did increase it (p=0.036). We did not observe signifcant changes in other brain areas studied. Conclusions: This study shows that genistein may have a role in therapeutics to delay the onset of Alzheimer’s dementia in patients with prodromal Alzheimer’s disease. These encouraging results indicate that this should be followed up by a new study with more patients to further validate the conclusion that arises from this study., This work was supported by the following grants: CB16/10/00435 (CIBERFES) from Instituto de Salud Carlos III, (PID2019-110906RB-I00/ AEI/10.13039/501100011033) and RED2018-102576-T from the Spanish Ministry of Innovation and Science, PROMETEO/2019/097 from “Consellería de Innovación, Universidades, Ciencia y Sociedad Digital de la Generalitat Valen ciana” and EU Funded H2020- DIABFRAIL-LATAM (Ref: 825546), European Joint Programming Initiative “A Healthy Diet for a Healthy Life” (JPI HDHL) and of the ERA-NET Cofund ERA-HDHL (GA N° 696295 of the EU Horizon 2020 Research and Innovation Programme) and Fundación Ramón Areces y Fundación Soria Melguizo. to J.V. and Grant PID2020-113839RB-I00 funded by MCIN/ AEI/10.13039/501100011033, PCIN-2017-117 of the Ministry of Economy and Competitiveness, and the EU Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ (JPI HDHL INTIMIC-085) to CB. We also acknowledge funding from the Spanish Ministry of Science, Innovation, and Universities (RTI2018099200-B-I00), the Generalitat of Catalonia, Agency for management of University and Research Grants (2017SGR696) and the Department of Health (SLT002/16/00250) to RP. Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-fnanced with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020). M.J. is a “Serra Hunter” Fellow.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models

  • Costa-Machado, Luis Filipe
  • García-Domínguez, Esther
  • McIntyre, Rebecca L.
  • López-Aceituno, José Luis
  • Ballesteros-González, Álvaro
  • Tapia-González, Andrea
  • Fabregat-Safont, David
  • Eisenberg, Tobias
  • Gómez, Jesús
  • Plaza, Adrian
  • Sierra-Ramírez, Aranzazu
  • Pérez, Manuel
  • Villanueva-Bermejo, David
  • Fornari, Tiziana
  • Loza, María Isabel
  • Herradón, Gonzalo
  • Hofer, Sebastian J.
  • Magnes, Christoph
  • Madeo, Frank
  • Duerr, Janet S.
  • Pozo, Oscar J.
  • Galindo, Maximo-Ibo
  • Pino, Isabel del
  • Houtkooper, Riekelt H.
  • Megías, Diego
  • Viña, José
  • Gómez-Cabrera, Mari Carmen
  • Fernández-Marcos, Pablo José
Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis., L.F.C.-M. was supported by the IMDEA Food institute and by a PhD Fellowship from the Portuguese Foundation for Science and Technology (FCT‐MCTES, SFRH/BD/124022/2016). Work in the laboratory of P.J.F.-M. was funded by the IMDEA Food Institute, the Ramón Areces Foundation (CIVP18A3891), the AECC (SIRTBIO, LABAE18008FERN), the MICINN (SAF2017-85766-R and PRPPID2020-114077RB-I00) co-funded by the European Regional Development Fund, and a Ramon y Cajal Fellowship (MICINN, RYC-2017-22335). J.L.L.-A. was funded by the Spanish Ministry of Science and Innovation (MICINN) (PTA2017‐14689‐I). Work in FreshAge laboratory was funded by: Instituto de Salud Carlos III CB16/10/00435 (CIBERFES), (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science; FGCSIC/PSLINTERREG/FEDER; PROMETEO/2019/097 de “Consellería de Sanitat de la Generalitat Valenciana” and EU Funded H2020- DIABFRAIL-LATAM (Ref: 825546). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana). Support from Ramón Areces Fundation and Soria Melguizo Foundation is also acknowledged. E.G.-D. was a recipient of a predoctoral grant financed by the Spanish Ministry (FPU18/05350). Work in the laboratory of IdP was funded by the MICINN (RTI2018-100872-J-I00) and PlaGenT excellence research program of the Valencian regional government (CIDENGENT/2019/044). Work in the laboratory of M.-I.G. was funded by PROMETEU/2018/135 from “Consellería, de Sanitat de la Generalitat Valenciana” and part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020). F.M. is grateful to the Austrian Science Fund FWF (SFB-LIPOTOX F3007 & F3012, W1226, P29203, P29262, P27893, and P31727); the Austrian Federal Ministry of Education, Science and Research and the University of Graz for grants Unkonventionelle Forschung-InterFast and ysleep (BMWFW-80.109/0001-WF/V/3b/2015) and the field of excellence program BioHealth. We acknowledge support from NAWI Graz, the BioTechMed-Graz agship project EPIAge. T.E. acknowledges support from Austrian Science Fund FWF (P 33957 and TAI 602 1000). Work in the laboratory of R.H.H. was financially supported by a VIDI grant from ZonMw (no. 91715305). J.S.D. was supported by Ohio University. D.F.-S. acknowledges Ministerio de Universidades in Spain for his Margarita Salas postdoctoral grant (Ref. MGS/2021/15). The CGC group is funded by NIH Office of Research Infrastructure Programs (P40 OD010440)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models

  • Costa-Machado, Luis Filipe
  • Fabregat-Safont, David
  • Pozo Mendoza, Óscar J., 1975-
  • Fernandez-Marcos, Pablo J.
Reversible and sub-lethal stresses to the mitochondria elicit a program of compensatory responses that ultimately improve mitochondrial function, a conserved anti-aging mechanism termed mitohormesis. Here, we show that harmol, a member of the beta-carbolines family with anti-depressant properties, improves mitochondrial function and metabolic parameters, and extends healthspan. Treatment with harmol induces a transient mitochondrial depolarization, a strong mitophagy response, and the AMPK compensatory pathway both in cultured C2C12 myotubes and in male mouse liver, brown adipose tissue and muscle, even though harmol crosses poorly the blood-brain barrier. Mechanistically, simultaneous modulation of the targets of harmol monoamine-oxidase B and GABA-A receptor reproduces harmol-induced mitochondrial improvements. Diet-induced pre-diabetic male mice improve their glucose tolerance, liver steatosis and insulin sensitivity after treatment with harmol. Harmol or a combination of monoamine oxidase B and GABA-A receptor modulators extend the lifespan of hermaphrodite Caenorhabditis elegans or female Drosophila melanogaster. Finally, two-year-old male and female mice treated with harmol exhibit delayed frailty onset with improved glycemia, exercise performance and strength. Our results reveal that peripheral targeting of monoamine oxidase B and GABA-A receptor, common antidepressant targets, extends healthspan through mitohormesis., Work in the laboratory of P.J.F.-M. was funded by the IMDEA Food Institute, the Ramón Areces Foundation (CIVP18A3891), the AECC (SIRTBIO, LABAE18008FERN), the MICINN (SAF2017-85766-R and PRPPID2020-114077RB-I00) co-funded by the European Regional Development Fund, and a Ramon y Cajal Fellowship (MICINN, RYC-2017-22335). J.L.L.-A. was funded by the Spanish Ministry of Science and Innovation (MICINN) (PTA2017‐14689‐I). Work in FreshAge laboratory was funded by: Instituto de Salud Carlos III CB16/10/00435 (CIBERFES), (PID2019-110906RB-I00/AEI/10.13039/501100011033) from the Spanish Ministry of Innovation and Science; FGCSIC/PSLINTERREG/FEDER; PROMETEO/2019/097 de “Consellería de Sanitat de la Generalitat Valenciana” and EU Funded H2020- DIABFRAIL-LATAM (Ref: 825546). Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana). Support from Ramón Areces Fundation and Soria Melguizo Foundation is also acknowledged. E.G.-D. was a recipient of a predoctoral grant financed by the Spanish Ministry (FPU18/05350). Work in the laboratory of IdP was funded by the MICINN (RTI2018-100872-J-I00) and PlaGenT excellence research program of the Valencian regional government (CIDENGENT/2019/044). Work in the laboratory of M.-I.G. was funded by PROMETEU/2018/135 from “Consellería, de Sanitat de la Generalitat Valenciana” and part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020). F.M. is grateful to the Austrian Science Fund FWF (SFB-LIPOTOX F3007 & F3012, W1226, P29203, P29262, P27893, and P31727); the Austrian Federal Ministry of Education, Science and Research and the University of Graz for grants Unkonventionelle Forschung-InterFast and ysleep (BMWFW-80.109/0001-WF/V/3b/2015) and the field of excellence program BioHealth. We acknowledge support from NAWI Graz, the BioTechMed-Graz agship project EPIAge. T.E. acknowledges support from Austrian Science Fund FWF (P 33957 and TAI 602 1000). Work in the laboratory of R.H.H. was financially supported by a VIDI grant from ZonMw (no. 91715305). J.S.D. was supported by Ohio University. D.F.-S. acknowledges Ministerio de Universidades in Spain for his Margarita Salas postdoctoral grant (Ref. MGS/2021/15). The CGC group is funded by NIH Office of Research Infrastructure Programs (P40 OD010440).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial

  • José, Viña
  • Escudero, Joaquín
  • Baquero, Miquel
  • Cebrián, Mónica
  • Carbonell Asíns, Juan Antonio
  • Muñoz, José Enrique
  • Satorres, Encarnación
  • Meléndez, Juan Carlos
  • Ferrer Rebolleda, José
  • Cózar Santiago, Mª Del Puig
  • Santabárbara Gómez, Jose Manuel
  • Jové Font, Mariona
  • Pamplona Gras, Reinald
  • Tarazona Santabalbina, Francisco José
  • Borrás, Consuelo
Background: Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics. Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet efective substances are recommended. There is a need to develop new drugs to delay Alzheimer’s dementia. We have taken a nutritional supplement approach with genistein, a chemically defned polyphenol that acts by multimodal specifc mechanisms. Our group previously showed that genistein supplementation is efective to treat the double transgenic (APP/PS1) AD animal model. Methods: In this double-blind, placebo-controlled, bicentric clinical trial, we evaluated the efect of daily oral supplementation with 120 mg of genistein for 12 months on 24 prodromal Alzheimer’s disease patients. The amyloidbeta deposition was analyzed using 18F-futemetamol uptake. We used a battery of validated neurocognitive tests: Mini-Mental State Exam (MMSE), Memory Alteration Test (M@T), Clock Drawing Test, Complutense Verbal Learning Test (TAVEC), Barcelona Test-Revised (TBR), and Rey Complex Figure Test. Results: We report that genistein treatment results in a signifcant improvement in two of the tests used (dichotomized direct TAVEC, p=0.031; dichotomized delayed Centil REY copy p=0.002 and a tendency to improve in all the rest of them. The amyloid-beta deposition analysis showed that genistein-treated patients did not increase their uptake in the anterior cingulate gyrus after treatment (p=0.878), while placebo-treated did increase it (p=0.036). We did not observe signifcant changes in other brain areas studied. Conclusions: This study shows that genistein may have a role in therapeutics to delay the onset of Alzheimer’s dementia in patients with prodromal Alzheimer’s disease. These encouraging results indicate that this should be followed up by a new study with more patients to further validate the conclusion that arises from this study., This work was supported by the following grants: CB16/10/00435 (CIBERFES) from Instituto de Salud Carlos III, (PID2019-110906RB-I00/ AEI/10.13039/501100011033) and RED2018-102576-T from the Spanish Ministry of Innovation and Science, PROMETEO/2019/097 from “Consellería de Innovación, Universidades, Ciencia y Sociedad Digital de la Generalitat Valen ciana” and EU Funded H2020- DIABFRAIL-LATAM (Ref: 825546), European Joint Programming Initiative “A Healthy Diet for a Healthy Life” (JPI HDHL) and of the ERA-NET Cofund ERA-HDHL (GA N° 696295 of the EU Horizon 2020 Research and Innovation Programme) and Fundación Ramón Areces y Fundación Soria Melguizo. to J.V. and Grant PID2020-113839RB-I00 funded by MCIN/ AEI/10.13039/501100011033, PCIN-2017-117 of the Ministry of Economy and Competitiveness, and the EU Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ (JPI HDHL INTIMIC-085) to CB. We also acknowledge funding from the Spanish Ministry of Science, Innovation, and Universities (RTI2018099200-B-I00), the Generalitat of Catalonia, Agency for management of University and Research Grants (2017SGR696) and the Department of Health (SLT002/16/00250) to RP. Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-fnanced with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020). M.J. is a “Serra Hunter” Fellow.